Coronary heart failure, also known as congestive heart failure or end-stage heart failure, refers to patients who continue to have apparent heart failure symptoms (such as difficulty breathing, shortness of breath, dizziness) and symptoms after optimized medication, and who repeatedly become hospitalized due to acute heart failure. Heart failure is the final stage of various heart diseases, refers to decreased pulmonary function and inability to meet the metabolic needs of the body. The underlying causes of uncontrollable heart failure are various organological heart diseases, including coronary heart disease (CHD), expansionary heart disease, hypertensive heart disease, coronary artery disease, cardiomyopathy, etc.
Factors that cause heart failure that are 'uncontrollable' include: continuous progression of heart disease; recurrent heart failure or reoccurrent stroke; persistent unremoved inducements such as infection; rapid heart rhythm abnormalities (CHD); poor blood control; anemia; thyroid abnormalities; electrolyte disorders; drug-dependent disorders; and complications in the treatment of pneumonia with other kidney dysfunction; chronic disease. The clinical manifestations of incurable heart failure are severe. Left-sided heart failure is mainly characterized by difficulty breathing at work, nighttime respiratory difficulties, shortness of breath, coughing and coughing and pink bubbles; right-sided heart failure is mainly characterized by lower extremity dizziness, venous thrombosis, liver, abdominal hemorrhage, gastrointestinal bleeding, resulting in appetite, diarrhea, nausea.
Patient activity tolerance decreases significantly, mild activity is stimulated, and patients are hospitalized repeatedly. Diagnosis of intracranial heart failure must be based on the diagnosis of heart failure and assess the severity of the condition and the causes of the intracranial heart failure. Examinations include: significantly elevated cerebral palsy (BNP or NT-proBNP), cardiac ultrasound evaluation of cardiac function (RBP), cardiac electrograms, chest X-rays, hepatic function, electrolysis, etc.
When necessary, coronary artery imaging, cardiac magnetic resonance imaging to determine the cause. Treatment of intracranial heart failure requires multidisciplinary comprehensive management. In terms of drug treatment, optimisation is based on the 'new four linkages': vascular neurotransmitter receptor macrophenease inhibitors (ARNI), β-receptor blockers, solidified sodium receptor antagonists, SGLT-2 inhibitors, etc.
, tailored according to blood pressure, heart rate, serum function; urine is used to reduce fluid retention, but patients with difficulty may require large doses or combined urine. Serious patients need continuous intravenous positive muscle medication, or use left ventricular assisted devices (artificial heart) as a bridge or terminal treatment; heart transplantation is the most effective treatment for end-stage heart failure, but with limited supplies. At the same time, the intake of hydrochloride (about 1500 ml/day) must be strictly controlled.
[!--page.url--]